Fate Therapeutics, Inc. Forecast, price target & analysts
Fate Therapeutics, Inc. Target price 2026 - Analyst rating & recommendation
Fate Therapeutics, Inc. Classifications & Recommendation
Fate Therapeutics, Inc. Price Target
| Target Price | $5.61 |
| Price | $2.38 |
| Potential |
135.71%
register free of charge
|
| Number of Estimates | 10 |
|
10 Analysts have issued a price target Fate Therapeutics, Inc. 2027 .
The average Fate Therapeutics, Inc. target price is $5.61.
This is
135.71%
register free of charge
$8.40
252.94%
register free of charge
$2.22
6.64%
register free of charge
|
|
| A rating was issued by 18 analysts: 11 Analysts recommend Fate Therapeutics, Inc. to buy, 7 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Fate Therapeutics, Inc. stock has an average upside potential 2027 of
135.71%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 6.65 | 5.73 |
| 51.21% | 13.80% | |
| EBITDA Margin | -2,027.07% | -2,122.92% |
| 56.47% | 4.73% | |
| Net Margin | -2,049.92% | -2,187.84% |
| 50.01% | 6.73% |
14 Analysts have issued a sales forecast Fate Therapeutics, Inc. 2026 . The average Fate Therapeutics, Inc. sales estimate is
This results in the following potential growth metrics:
4 Analysts have issued an Fate Therapeutics, Inc. EBITDA forecast 2026. The average Fate Therapeutics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
14 Fate Therapeutics, Inc. Analysts have issued a net profit forecast 2026. The average Fate Therapeutics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
| Dec '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.15 | -1.07 |
| 29.88% | 6.96% | |
| P/E | negative | |
| EV/Sales | 25.00 |
14 Analysts have issued a Fate Therapeutics, Inc. forecast for earnings per share. The average Fate Therapeutics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Fate Therapeutics, Inc....
Current Fate Therapeutics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Wells Fargo |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Piper Sandler |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| Wedbush |
Locked
➜
Locked
|
Locked | Aug 14 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jun 08 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | May 04 2026 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Oct 31 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Oct 27 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Wells Fargo:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Piper Sandler:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Aug 14 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jun 08 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
May 04 2026 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Oct 31 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Oct 27 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
